Synexus

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Titration, Multi-center Study to Evaluate the Safety and Efficacy of Subcutaneous MANP When Administered Once Daily for 42 Days in Participants with Difficult to Control Hypertension/Resistant Hypertension.